Cardiology

Patients with NAFLD were more likely to have comorbidities, including diabetes, hypertension, chronic respiratory disease, hypothyroidism, chronic kidney disease, sleep apnea, and hyperlipidemia.

In his latest column, Gregory Weiss, MD, examines a pair of studies examining different causes of cardiometabolic events from contemporary data and provides perspective on the implications of their findings.

Experts in cardiology share their thoughts on patient/clinician communication and treatment customized to the individual patient.

Drs Erin Michos, Pam Taub, Robert Busch, Alison Bailey, and Jorge Plutzky discuss the impact of lipid lowering on the risk of ASCVD.

Announced on October 19, the American Heart Association's Cardiogenic Shock Registry powered by Get With The Guidelines was created with the intent of providing researchers with access to real-time data related to care and outcomes of patients with cardiogenic shock in the US to help improve management.

National coverage of MTMs for diet-related diseases may be associated with 1.6 million averted hospitalizations and net cost savings of $13.6 billion annually.

Study data show 64.3% of patients self-administering etripamil converted to sinus rhythm within 30 minutes compared to 31.2% on placebo.

Announced on October 17, the US FDA's expanded indication for Medtronic's SelectSecure™ MRI SureScan Model 3830 cardiac lead makes it the first and only device with FDA approval for conduction system pacing, according to a release from Medtronic.

AI-enabled retinal imaging can accurately predict CVD and death, without the need for blood tests or BP measurement, according to the findings.

At PER’s 6th Annual Cardio-Endo-Renal Collaborative, Aruna Pradhan, MD, MPH, provides perspective on a recent AHA scientific statement on use of patient-reported outcomes in care of peripheral artery disease.

"When you decrease the weight, that also improves the metabolic parameters. The A1c goes down, it helps bring the fasting glucose down, including even liver parameters," she explained.

Published on October 13, the latest scientific statement from the American Heart Association highlights the current role of patient-reported outcome measures in the management of peripheral artery disease as well as future considerations for optimizing this role and benefits in care.

An interview with Dr. Vega regarding atrial fibrillation and clinical manifestations for ADPKD.

A panel of experts comments on the importance of risk assessment in ASCVD as well as factors that contribute to risks.

Drs Erin Michos, Pam Taub, Robert Busch, Alison Bailey, and Jorge Plutzky, provide an overview of the prevalence of atherosclerotic cardiovascular diseases (ASCVD) and hypercholesterolemia in the development of ASCVD.

The beneficial effect of intensive BP control on cardiovascular and all-cause mortality was attenuated during 4.5 years of post-trial after SPRINT.

A systematic review and meta-analysis with data from more than 55 million individuals is providing new insight into the relative risk of myocarditis following a COVID-19 infection compared with vaccination.

Paxlovid is effective in patients with existing heart disease, but has significant DDIs with commonly used cardiovascular medications.

Mobile health technology to detect AF led to a high rate of false positives in patients with certain cardiac conditions.

Sotatercept added to background therapy demonstrated significant improvement in exercise capacity compared to placebo.

The approval indicates the subcutaneous loop diuretic for the at-home treatment of congestion in adults with NYHA Class II/III chronic heart failure.

Our latest cardiology case report features a patient in their mid-70’s presenting to the hospital with reports of feeling sluggish and a heart rate in the 40s. Check out the EKG and determine the correct diagnosis.

The risk of primary composite cardiovascular outcomes was reduced by 47%, while the risk of secondary cardiovascular disease outcomes was reduced by 50% in patients with bariatric surgery compared to nonsurgical patients.

The observed reductions in CV mortality in patients treated with dapagliflozin were primarily due to lower rates of HF and sudden death.

Martin Maron, MD, sits down to discuss aficamten, the SEQUOIA-HCM trial, and the most pressing unmet needs in the management of hypertrophic cardiomyopathy.